EUREPA V 0.5/0.2 MG
Rs 147.7 10 % Off
Package size
Estimate Delivery by:
Delivering to
Easy 7 days return available
EUREPA V 0.5/0.2 MG
0.2mg Tablet combines Repaglinide and Voglibose to effectively manage type 2 diabetes. Repaglinide promotes insulin secretion from the pancreas, while Voglibose inhibits the enzymes responsible for carbohydrate breakdown, reducing post-meal glucose spikes. This dual-action approach offers robust blood sugar control. Ideal for use alongside diet and exercise, Eurepa V provides a flexible dosing regimen tailored to individual needs. Regular monitoring and healthcare professional guidance are essential for optimal results and safety.
Product Highlights and Usage:
Combination Therapy: Contains Repaglinide 0.5 mg and Voglibose 0.2 mg for comprehensive diabetes management. Blood Sugar Control: Helps regulate blood glucose levels in type 2 diabetes patients. Insulin Release Stimulation: Repaglinide stimulates pancreatic insulin release. Carbohydrate Absorption Inhibition: Voglibose inhibits carbohydrate digestion enzymes to lower post-meal blood sugar. Flexible Dosing: Allows for adjustment based on individual glucose monitoring and meal patterns.
How it works:
EUREPA V 0.5/0.2MG TABLET combines Repaglinide and Voglibose. Repaglinide enhances insulin release from the pancreas, while Voglibose inhibits ?-glucosidase, an intestinal enzyme that breaks down complex sugars into simple sugars. This dual action lowers blood glucose levels, aiding in the management of type-2 diabetes mellitus.
Directions for use:
Follow your physician's instructions when taking EUREPA V 0.5/0.2MG TABLET. Swallow it with a glass of water. Do not crush or chew the tablet. Your doctor will determine the appropriate dosage and duration of treatment based on your age, body weight, and medical condition.
Warning & Precaution:
Pregnancy EUREPA V 0.5/0.2MG TABLET is generally not recommended for use during pregnancy and in women planning for pregnancy. Consult and inform your doctor before taking EUREPA V 0.5/0.2MG TABLET. Breastfeeding EUREPA V 0.5/0.2MG TABLET is generally not recommended for use in breastfeeding women. Consult and inform your doctor before taking EUREPA V 0.5/0.2MG TABLET. Driving and using machines Use EUREPA V 0.5/0.2MG TABLET with caution. Avoid driving or operating machinery if you experience signs of high or low blood sugar, as it may endanger yourself or others. Alcohol Consult your doctor regarding alcohol consumption while taking EUREPA V 0.5/0.2MG TABLET, as it may alter the effect of the medicine. Kidney Use EUREPA V 0.5/0.2MG TABLET with caution in patients with kidney problems such as mild, moderate, or severe renal impairment, and in patients undergoing dialysis. Consult and inform your doctor before taking the medicine. Liver EUREPA V 0.5/0.2MG TABLET is not recommended for use in patients with moderate to severe liver disease. Consult and inform your doctor before taking the medicine. Allergy Do not take EUREPA V 0.5/0.2MG TABLET if you are allergic to Repaglinide, Voglibose, or any other ingredients of this medicine. Use in Pediatrics EUREPA V 0.5/0.2MG TABLET is not recommended for use in children and adolescents (aged below 18 years). Consult and inform your doctor before taking EUREPA V 0.5/0.2MG TABLET. Use in Geriatrics EUREPA V 0.5/0.2MG TABLET is not recommended for use in elderly patients (aged above 75 years). Consult and inform your doctor before taking EUREPA V 0.5/0.2MG TABLET.
Super Admin
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s
Recent Posts
-
October 18, 2015
-
October 18, 2015
Products
-
275$
-
137.64$